Tiziana Life Sciences Share Price (TILS)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Tiziana Life Sciences Plc LSE:TILS London Ordinary Share GB00BKWNZY55 ORD 3P
  Price Change % Change Share Price Shares Traded Last Trade
  -4.00 -2.33% 168.00 1,547,661 16:35:09
Bid Price Offer Price High Price Low Price Open Price
160.00 165.00 174.00 162.50 168.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -7.85 -5.40 320
Last Trade Time Trade Type Trade Size Trade Price Currency
17:07:31 O 12,514 168.30 GBX
Related Shares
Astrazeneca (AZN), Glaxosmithkline (GSK), Motif Bio (MTFB), Bermele (BERM)

Tiziana Life Sciences (TILS) Latest News

Tiziana Life Sciences News

Date Time Source Headline
11/8/202008:49RNSNONTiziana Life Sciences PLC BTIG's Virtual Biotechnology Conference
10/8/202007:21ALNCFAlliance News Flash Headline
10/8/202007:00UKREGTiziana Life Sciences PLC Holding(s) in Company
05/8/202022:03ALNCUK TRADING UPDATE SUMMARY: Airtel And Telkom Abort Kenya Combination
05/8/202016:00UKREGTiziana Life Sciences PLC Closing of $57.25 Million Offering
04/8/202019:16ALNCUK TRADING UPDATE SUMMARY: Brickability Recovering Well From Pandemic
04/8/202007:00UKREGTiziana Life Sciences PLC Expedited Clinical Development Plan
03/8/202018:22ALNCUK TRADING UPDATE SUMMARY: Tiziana Offering to Raise GBP57 Million
03/8/202007:00UKREGTiziana Life Sciences PLC Issue of Equity
03/8/202006:56ALNCIN BRIEF: Tiziana Submits Covid-19 Patent Application For Foralumab
More Tiziana Life Sciences News
Tiziana Life Sciences Takeover Rumours

Tiziana Life Sciences (TILS) Discussions and Chat

Tiziana Life Sciences Forums and Chat

Date Time Title Posts
14/8/202020:39A new cancer research company to watch9,008
14/8/202007:24Short changed!35

Add a New Thread

Tiziana Life Sciences (TILS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-08-14 17:56:24168.3012,51421,061.06O
2020-08-14 17:07:14166.908,95514,945.90O
2020-08-14 17:04:13165.0010,00016,500.00O
2020-08-14 16:56:11176.007,24212,745.92O
2020-08-14 16:28:58161.004,5457,317.45O
View all Tiziana Life Sciences trades in real-time

Tiziana Life Sciences (TILS) Top Chat Posts

DateSubject
14/8/2020
09:20		Tiziana Life Sciences Daily Update: Tiziana Life Sciences Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker TILS. The last closing price for Tiziana Life Sciences was 172p.
Tiziana Life Sciences Plc has a 4 week average price of 145p and a 12 week average price of 81.50p.
The 1 year high share price is 295p while the 1 year low share price is currently 24.50p.
There are currently 190,559,823 shares in issue and the average daily traded volume is 1,666,273 shares. The market capitalisation of Tiziana Life Sciences Plc is £320,140,502.64.
Read Full Thread
Reply
02/8/2020
12:44		yidarmytom: pwhite “ShareProphets has no more idea than you or I where TILS share price is going. However the rationale for shorting the price is as clear as daylight” That’s also wrong, I have a better idea than them, it’s going up. You said it was going down a month ago and everyone should sell. What happened?
Read Full Thread
Follow
Reply
02/8/2020
11:04		pwhite73: yidarmyTom ShareProphets has no more idea than you or I where TILS share price is going. However the rationale for shorting the price is as clear as daylight. TILS has noting in its pipeline that would even remotely suggest commercialisation. Their lead drug Foralumab is not even theirs. They are only licensing the application of it through nasal administration. Foralumab itself is about 10 years and £1.5 billion away from commercialisation assuming it even gets that far. If you think the road ahead is expensive and rocky for Foralumab its even more so for StemprintER. TILS are drawing comparisons between StemprintER and Oncotype DX RNS 29/05/2020 - "...demonstrating the superiority of StemPrintER stem cell based genomic prognostic tool versus the market leader, Oncotype DX, in predicting recurrence in ER+/HER2- postmenopausal breast cancer patients." That is quite some statement and if it were true would revolutionise the entire world system of testing for breast cancer given the below:- https://newsroom.genomichealth.com/news-releases/news-release-details/following-nices-exclusive-recommendation-nhs-england-agrees "Following NICE's Exclusive Recommendation, NHS England Agrees to Access Program for Oncotype DX® Breast Cancer Test" "With half a million patients tested in more than 70 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment" Speak Later
Read Full Thread
Follow
Reply
02/8/2020
07:57		pwhite73: michael boyle1 I can't disagree with any of that. However at some point and soon the market will ask TILS - "other than share issues what have you got that will actually generate any money for the company anytime now or in the foreseeable future." It is at this point that TILS share price will begin to align itself with zero revenues and annual losses of £7 million.
Read Full Thread
Follow
Reply
25/7/2020
23:56		cumnor: I would be surprised if StemPrinter goes to OKYO, as has been suggested, or if there was some sort of 'merger' between the companies, as it makes, on the surface at least, little sense. StemPrinter is a valuable asset, worth several hundred million to TILS at this stage imo-a couple of billion if it got the blessing of regulators Stateside and floated on Nasdaq-so lets hope there is no 'talking down' its potential as part of a demerger. OKYO is no more entitled to Tils' best asset, StemPrinter, than is Barclays, GSK or Rio Tinto, without paying the full market price. An open market sale using IBs could determine this. Okyo, were it interested in Stem, does not appear to have the money or the means to pay for Stem-unless something dramatically changes. Its paper is irrelevant imo given the recent huge and sudden rise in its share price on little or no substantial news, and with huge numbers of shares issued at 0.5p and warrants to match, so it can hardly inspire investors to believe this rise could be sustained on the basis of its present portfolio. So I have no idea how this could justifiably happen, irrespective of its close connections to Tils at board level. imo dyor
Read Full Thread
Follow
Reply
17/7/2020
20:20		pwhite73: terry508 I haven't seen any of that potential. All you ever get from this company is a load of waffle. Look at Verona up 100% today after having raised $200 million as its lead product goes into Phase III trial. The final stage before FDA approval "Verona Pharma intends to use the net proceeds from the Financing primarily to fund its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy)" Ironically its using a Nebulizer although TILS has convinced all of you it has an exclusive patent on Nebulized inhalers. Verona is way ahead on the curve yet it has a market cap of only £100 million compare to TILS with a market cap of £300 million. TILS has absolutely nothing that is even close to commercialisation. The directors were going to delist the company at the start of the year, Covid-19 has thrown the listing a lifeline. All credit to the directors for knowing how to talk the talk. But closer inspection shows they're doing nothing but jumping from hot topic to hot topic. They claim their TZLS-501 is more potent than Roches Actemra which is actually on the market having passed on the necessary regulatory trials and having tested the product on thousands of patients. TZLS-501 hasn't even entered Phase 1 yet. What an outlandish statement to make. Whatever is in vogue TILS is there whether it be Alzheimers, Cancer, Coronavirus or Multiple Sclerosis. I'm willing to be corrected here but I don't belief TILS has ever brought a drug or product to market. I have given you warning after warning after warning. Some of you think because the share price has risen sharply again its scared me off, well it hasn't. People here claiming they've banked £10k, £20k, £50k. One or two may have made decent money but most are liars. What's happened to the re-registration to Bermuda, what's happened to the StemprintER flotation. TILS is a classic case of the Emperor has no clothes. Not if but when it crashes you will lose everything. Be careful.
Read Full Thread
Follow
Reply
07/7/2020
08:45		vikingwarrier: hxxps://www.proactiveinvestors.com/companies/news/921274/tiziana-life-sciences-worth-us25-per-ads-according-to-hc-wainwright-921274.html The target follows the biotech's recent updates on two projects: foralumab and StemPrintER. Tiziana Life Science PLC (LON:TLSA Nasdaq:TSLA)) is worth around 300% more than the current share price based on just two of its potential pipeline developments, according to HC Wainwright. The broker reiterated its US$25 price target and 'buy' rating for the Nasdaq-listed ADS following the biotech's recent updates on two projects: foralumab and StemPrintER. This target, though excludes any contribution in future from foralumab beyond Crohn's disease or milciclib in cancers beyond HCC (liver); or anything from StemPrintER or TZLS-501 (coronavirus), said the broker. “Positive clinical data with foralumab for indications representing massive markets like AD (Alzheimer’s) and MS (multiple sclerosis) could thus constitute a considerable upside to our assumptions,” added analyst Raghuram Selvaraju. Earlier this week, Tiziana reported that Howard Weiner, the chairman of its scientific advisory board, had received a grant from the NIH to investigate foralumab, its nasally delivered anti-CD3 monoclonal antibody (mAb), as a possible Alzheimer's treatment. The grant followed a demonstration by Weiner that unexpectedly found that the nasally delivered anti-CD3 modulated brain microglia in animal models. Activated microglia have been shown in studies to essentially 'erase' memories in mice, said Selvaraju. Tiziana has a worldwide exclusive licence for nasal administration of anti-CD3 mAbs for the treatment of neurodegenerative diseases including Alzheimer’s, noted the analyst, from Brigham and Women’s Hospital, Harvard Medical School, Boston. Phase I trials have focused on its use as a treatment for multiple sclerosis and Crohn’s disease, respectively, said Selvaraju but plans are in train for phase II studies in both conditions for nasally and orally administered formulations. Selvaraju expects a proof-of-concept study might start for oral foralumab as a treatment for Crohn’s and intra-nasal foralumab for multiple sclerosis within six to 12 months. Tiziana is also working on an inhaled form to address lung inflammation and dysfunction in patients infected with the SARS-CoV-2 coronavirus, which is responsible for the COVID-19 pandemic. On StemPrintER, Selvaraju added that validation data presented at ASCO in posters provided compelling evidence of its predictive power for breast cancer and its superiority over the current standard Oncotype DX. TILS is with the 2 big company Covid-19 treatments, and TILS has already shown 2 distinct advantages over Roche's Actemra and Regeneron’s Kevzara. Hence why TILS has had to file the patent for this treatment very quickly. They have a major competitive advantage going forward - and none of this has been reflected in the previously over sold prices. The recent news is that Ventilators are causing permanent lung damage, because they are forcing oxygen in, which is not being totally used by the lungs due to the lung infection. Therefore the infection has to be cleared or the patience dies. TILS targeting drug and procedure (superior) and targets the lungs to clear the infection that is actually causing death. :) / this is home run, considering to major drugs have worked in China and these are intravenous delivery only and do not deliver directly to the lungs. They also caused poor immune responses because they’re humanised and not like TILS drug which is human ready and will not have any impact on human immune system. TZLS-501 by Tiziana Life Sciences Tiziana Life Sciences is developing its monoclonal antibody named TZLS-501 for the treatment of COVID-19. TZLS-501 is a human anti-interleukin-6 receptor (IL-6R), which helps in preventing lung damage and elevated levels of IL-6. The drug works by binding to IL-6R and depleting the amount of IL-6 circulating in the body thereby reducing chronic lung inflammation. Actemra by Roche to treat coronavirus-related complications China approved the use of Roche’s Actemra for the treatment of severe complications related to coronavirus. Drugs like Actemra have the ability to prevent cytokine storms or overreaction of the immune system, which is considered as the main reason behind organ failure leading to death in some coronavirus patients. Actemra is also being evaluated in a clinical trial in China, which is expected to enrol 188 coronavirus patients. The clinical trial is expected to be conducted until May 10. Regeneron’s REGN3048-3051 and Kevzara Discovered by Regeneron, the combination of neutralising monoclonal antibodies REGN3048 and REGN3051 is being studied against coronavirus infection in a first-in-human clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The safety and tolerability of the drug will be studied in 48 patients. Both the antibodies bind to S-protein of MERS coronavirus. The intravenous administration of the drug in the mouse model of MERS resulted in the high-level neutralisation of the MERS coronavirus in circulating blood with reduced viral loads in the lungs. Regeneron has partnered with Sanofi to evaluated Kevzara, a fully-human monoclonal antibody, in a phase two/three clinical trial in patients with severe COVID-19 infection. Kevzara is approved for the treatment of rheumatoid arthritis and is known to block the interleukin-6 (IL-6) pathway, which causes an overactive inflammatory response in the lungs of COVID-19 patients. As the CEO says most people invested in TILs for other treatments and StemPrinter wasn't even on the radar until last week. Now that one product could be worth £17.50 for each share we hold. Exact Sciences OncotypeDX Recent valuations before StemPrinter was announced as successful in trials were that TILS was worth about 500p a share. but Tiziana Life Sciences is developing its monoclonal antibody named TZLS-501 for the treatment of COVID-19. TZLS-501 is a human anti-interleukin-6 receptor (IL-6R), which helps in preventing lung damage and elevated levels of IL-6 so the 500p valuation could be meaningless. it could be closer to £10 a share. It all depends on what happens here. Thats the basic share price potential. The StemPrinter news that it was a 40-50% improvement on the current market leader kind of came out of nowhere. Nobody had really taken much notice of this product before then. STEM though can be valued pretty accurately because 6 months ago Exact Sciences paid £2.8bn for a similar but inferior product. if STEM is 160m shares then each share would be valued at £17.50 maybe more but not really less. So we can place a current value on TILS of between £20-30 £20 without any COVID19 treatment £30 with. It might take a year to reach these prices or it might be quicker but one thing is for sure and that is you don't need to look at another share until this happens. It will be the easiest way you ever made money.
Read Full Thread
Follow
Reply
22/5/2020
08:07		pwhite73: The big mark ups at the bell on such news is not for you guys. If you try to sell they won't let you. The big mark up is to burn institutional shorts and spread betters who have a bet on falls. This will settle down. When properly analysed TILS share price will reflect StemPrintER is about to be hived off not even sold where shareholders can expect cash in exchange but hived off.
Read Full Thread
Follow
Reply
13/5/2020
18:49		raymond hill: window.googletag = window.googletag || {cmd: []}; googletag.cmd.push(function() { var mapping = googletag.sizeMapping(). addSize([1200, 0], [300, 250]). addSize([992, 0], [230,190]). addSize([768, 0], [170,140]). addSize([576, 0], [[510, 170], [468, 60], [300, 250], [300, 50], [320, 50], [320, 100]]). addSize([468, 0], [[468, 60], [300, 250], [300, 50], [320, 50], [320, 100]]). addSize([320, 0], [[300, 250], [300, 50], [320, 50], [320, 100]]). addSize([0, 0], []). build(); googletag.defineSlot('/6519473/LUX-Content_Sidebar', [[510, 170], [300, 250], [468, 60], [300, 50], [320, 100], [170, 140], [320, 50], [230, 190]], 'div-gpt-ad-1570110319358-0').defineSizeMapping(mapping).addService(googletag.pubads()); googletag.pubads().enableSingleRequest(); googletag.pubads().collapseEmptyDivs(); googletag.pubads().setTargeting('Domains', ['UK']).setTargeting('Content_type', ['News']); googletag.enableServices(); }); googletag.cmd.push(function() { googletag.display('div-gpt-ad-1570110319358-0'); }); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'hxxps://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-PLC3R3B'); Sign in News Live Market reports Trusts, ETFs. Funds Contributors Small caps Newsletters OTC Markets Topics Energy Health Mining Tech Finance Basic Materials Retail & consumer Telecoms & Networks Industry & services Utilities All topics... Spotlight Pharma & Biotech Coronavirus Cannabis Battery Metals Insights Deep dive Opinion Research Feature All insights... Research Companies Search A-Z Big caps Mid caps Small caps Micro Cap Nano Cap BeProactive How to BeProactive Success stripped down Explainers & education Evergreen columns Events Proactive Investors One2One Investor Forum London 2020-05-21 18:00:00 Proactive Investors One2One Investor Forum London 2020-05-28 18:00:00 Proactive Investors One2One Investor Forum London 2020-06-11 18:00:00 View all events My proactive Watch About Our board Our management team Our team Our journalists Careers Contact Legal Terms and conditions Privacy Cookies UK [...] USA [...] CA Watch MyProactive Feed Alerts Subscriptions Bookmarks Settings News Sections Most read news Live Market reports Trusts, ETFs. Funds Contributors Small caps Newsletters OTC Markets Ariana Resources in fine fettle as gold production climbs FTSE 100 finishes under 6,000 as US Fed warns on virus impact Gaming Realms targets international distribution and US expansion Ariana Resources higher as it completes initial earn-in work for Venus Minerals TUI and Aston Martin among key updates for Wednesday Metal Tiger notes Cobre has completed its acquisition of the remaining 20% of shares in Toucan Gold Mosman Oil and Gas says production continues at the Stanley field in Texas Gaming Realms rises as it inks deal with Hasbro to negotiate opportunities for Slingo brand Egdon Resources higher as Wressle progresses to first oil Taylor Wimpey to re-open show homes and sales centres in England and Wales Topics Sections Most read news Spotlight Energy Health Mining Tech Finance Basic Materials Retail & consumer Telecoms & Networks Industry & services Utilities All topics... Ariana Resources in fine fettle as gold production climbs FTSE 100 finishes under 6,000 as US Fed warns on virus impact Gaming Realms targets international distribution and US expansion Ariana Resources higher as it completes initial earn-in work for Venus Minerals TUI and Aston Martin among key updates for Wednesday Metal Tiger notes Cobre has completed its acquisition of the remaining 20% of shares in Toucan Gold Mosman Oil and Gas says production continues at the Stanley field in Texas Gaming Realms rises as it inks deal with Hasbro to negotiate opportunities for Slingo brand Egdon Resources higher as Wressle progresses to first oil Taylor Wimpey to re-open show homes and sales centres in England and Wales Pharma & Biotech Coronavirus Cannabis Battery Metals Insights Sections Most read news Deep dive Opinion Research Feature All insights... BATM joins the global effort to tackle the pandemic Premier African Minerals continues to build value Ariana Resources in fine fettle as gold production climbs Diversified Gas & Oil stable and in a position to strengthen despite market turmoil Pan African Resources set to benefit from stronger gold price Gaming Realms targets international distribution and US expansion ClearStar leverages technology for competitive edge in candidate screening sector Bluebird Merchant Ventures on course for first production after permit award Kavango Resources sees huge upside at KSZ in Botswana Union Jack Oil builds up strong portfolio of UK assets Research Companies Sections Search A-Z Big caps Mid caps Small caps Micro Cap Nano Cap BeProactive Sections Most read news How to BeProactive Success stripped down Explainers & education Evergreen columns Events Sections Proactive Investors One2One Investor Forum London 2020-05-21 18:00:00 Proactive Investors One2One Investor Forum London 2020-05-28 18:00:00 Proactive Investors One2One Investor Forum London 2020-06-11 18:00:00 View all events Sign in What are you searching for? Companies News See all companies matching See all news matching [...] HealthPharma & Biotech Ian Lyall 10:41 Mon 11 May 2020 Follow Ian on: Investor deep dive Tiziana Life Sciences upbeat on potential for coronavirus treatment read more > [...] Tiziana Life Sciences has four submissions accepted to virtual ASCO event The American Society of Clinical Oncology attracts the cream of the industry to its annual conference [...] The ASCO event will be online this year [...] PLC (LON:TILS, [...]) has said it will showcase data via four submissions at the virtual replacement for the world’s leading cancer conference. Leading the way are two poster sessions on StemPrintER at the American Society of Clinical Oncology (ASCO) summit. The technology is being developed to predict the potential recurrence of breast cancer. In one of those posters, there is a direct comparison of Tiziana's product with current market leader, Oncotype DX. A further two ‘e-abstracts’ assess the potential of the firm’s Milciclib drug candidate in treating hepatocellular carcinoma. "These data being presented at ASCO are significant for our oncology portfolio and highlight a complementary technology for detection of breast cancer," Dr Kunwar Shailubhai, chief executive and chief scientific officer of Tiziana said in a statement. "Of particular note is that one of these studies was selected to be part of a poster discussion session during the meeting.  “We look forward to sharing these critical data on our StemPrintER clinical diagnostic for ER+/HER2- breast cancer patients and its utility in potentially optimizing therapeutic decision-making, especially in the discussion of StemPrintER relative to the current market leader, Oncotype DX," he added. The information will be available from May 13 onwards, while the ASCO conference itself, which attracts the cream of the industry, runs from May 29-31. Below are the details of the submissions: Poster discussion sessions Abstract #1020: "Comparison of StemPrintER, a novel biology-based genomic predictor of distant recurrence in breast cancer, with Oncotype DX in the TransATAC cohort" Abstract #1057: "Integration of the stem cell biology-based genomic tool, StemPrintER, with clinicopathological parameters for the prediction of distant recurrence in ER+/HER2- breast cancer (BC) patients" e-abstracts e16711: "Phase 2a safety and efficacy of Milciclib, a pan-cyclin dependent kinase inhibitor, in unresectable, sorafenib-refractory or -intolerant hepatocellular carcinoma patients" e16634: "Safety and clinical activity of combination treatment with regorafenib and milciclib in liver transplant patients with hepatocellular carcinoma recurrence# The shares were trading 8% higher at 70p each, valuing the business at £113mln. ----ADDS SHARE PRICE--- Quick facts: Tiziana Life Sciences Price: 85.15 GBX AIM:TILS Market: AIM Market Cap: £136.89 m Follow [...] Add related topics to MyProactive Health Pharma & Biotech Small caps Tiziana Life Sciences Sign up for Newsletter Create your account: sign up and get ahead on news and events NO INVESTMENT ADVICE The above has been published by Proactive Investors Limited (the "Company") on its website and is made available subject to the terms and conditions of use of its website (see T&C ). ... FOR OUR FULL DISCLAIMER CLICK HERE Deep dive [...] Tiziana Life Sciences upbeat on potential for coronavirus treatment Most read Telecoms & Networks BT cancels dividend for two years to fund investment and coronavirus... 6 days, 7 hours ago Retail & consumer Booming video game industry can't continue to be overlooked by investors 2 days, 8 hours ago Finance British Land and Land Securities tipped to ride out UK property recession 2 days, 2 hours ago SP Angel Morning View - Condor Gold and more... 6 days, 7 hours ago More on this story data-story-type="2" data-id="918934" data-category-id="52" data-video-timestamp="15.59" data-has-short-video="" data-allow-popup="0" > Health Tiziana chief scientist discusses its 'pioneering' inhalation... 1 week ago data-story-type="1" data-id="917772" data-category-id="59" data-video-timestamp="---" data-has-short-video="" data-allow-popup="0" > Finance Coronavirus: what’s happening in the labs of pharma companies... 1 week, 2 days ago data-story-type="1" data-id="917056" data-category-id="47" data-video-timestamp="---" data-has-short-video="" data-allow-popup="0" > Health Tiziana Life Sciences upbeat on potential for coronavirus treatment 2 weeks, 2 days ago data-story-type="1" data-id="918197" data-category-id="53" data-video-timestamp="---" data-has-short-video="" data-allow-popup="0" > Health Tiziana Life Sciences files patent application for potential... 2 weeks, 2 days ago Watch data-story-type="2" data-id="918934" data-video-timestamp="15.59" data-category-id="52" data-has-short-video="" data-allow-popup="1" > Tiziana chief scientist discusses its 'pioneering' inhalation technology and... Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) CEO and chief scientific officer Kunwar Shailubhai discusses the recent excitement around inhalation and the direct delivery of drugs to lungs. ''It makes a lot of sense'', he says. Shailubhai says he's pleased he's covered this approach in his... 1 week ago data-story-type="2" data-id="918186" data-category-id="52" data-video-timestamp="12.37" data-has-short-video="" data-allow-popup="1" > Health Tiziana Life Sciences files patent for combinational treatment for... 2 weeks, 2 days ago data-story-type="2" data-id="918035" data-category-id="53" data-video-timestamp="10.10" data-has-short-video="" data-allow-popup="1" > Health Zak Mir talks 'post-crash market environment' and his picks of the... 2 weeks, 5 days ago data-story-type="2" data-id="917790" data-category-id="53" data-video-timestamp="45.10" data-has-short-video="" data-allow-popup="1" > Health Tiziana Life Sciences PLC - Proactive One2One Virtual Forum 3 weeks, 1 day ago data-story-type="2" data-id="917218" data-category-id="52" data-video-timestamp="06.01" data-has-short-video="" data-allow-popup="1" > Health Tiziana Life Sciences, Open Orphan, S4 Capital & planarTECH -... 4 weeks, 1 day ago Editor's picks data-story-type="1" data-id="919452" data-category-id="64" data-video-timestamp="---" data-has-short-video="" data-allow-popup="0" > [...] Finance Taylor Wimpey to re-open show homes and sales centres in England... 7 hours, 13 minutes ago data-story-type="1" data-id="919453" data-category-id="65" data-video-timestamp="---" data-has-short-video="" data-allow-popup="0" > [...] Industry & services Aston Martin keeps financing options open as coronavirus... 8 hours, 12 minutes ago data-story-type="1" data-id="919450" data-category-id="53" data-video-timestamp="---" data-has-short-video="" data-allow-popup="0" > [...] Retail & consumer Gaming Realms rises as it inks deal with Hasbro to negotiate... 8 hours, 46 minutes ago data-story-type="1" data-id="919456" data-category-id="64" data-video-timestamp="---" data-has-short-video="" data-allow-popup="0" > [...] Retail & consumer TUI plans operations overhaul with 8,000 job losses 10 hours, 1 minute ago data-story-type="1" data-id="919354" data-category-id="64" data-video-timestamp="---" data-has-short-video="" data-allow-popup="0" > [...] Telecoms & Networks Vodafone keeps dividend on redial as customer loyalty improves in... 1 day, 6 hours ago data-story-type="1" data-id="919377" data-category-id="53" data-video-timestamp="---" data-has-short-video="" data-allow-popup="0" > [...] Retail & consumer Gaming Realms reaping the benefits from shift to licensing 1 day, 7 hours ago data-story-type="1" data-id="919344" data-category-id="64" data-video-timestamp="---" data-has-short-video="" data-allow-popup="0" > [...] Tech Morrisons expands online activities as trading proves highly volatile 1 day, 9 hours ago data-story-type="1" data-id="919359" data-category-id="53" data-video-timestamp="---" data-has-short-video="" data-allow-popup="0" > [...] Mining Galantas expects to restart milling at the Omagh gold mine within... 1 day, 10 hours ago data-story-type="1" data-id="919356" data-category-id="64" data-video-timestamp="---" data-has-short-video="" data-allow-popup="0" > [...] Finance Land Securities to reassess whole business after gloomy... 1 day, 10 hours ago data-story-type="1" data-id="919355" data-category-id="53" data-video-timestamp="---" data-has-short-video="" data-allow-popup="0" > [...] Energy Gore Street Energy Storage Fund says construction has resumed at... 1 day, 10 hours ago RNS Tiziana Life Sci PLC - Second Price Monitoring Extn 6 hours, 39 minutes ago Tiziana Life Sci PLC - Price Monitoring Extension 6 hours, 45 minutes ago Tiziana Life Sci PLC - Holding(s) in Company 2 days, 6 hours ago Tiziana Life Sci PLC - ASCO Conference 2 days, 10 hours ago Tiziana Life Sci PLC - Second Price Monitoring Extn 6 days, 6 hours ago Tiziana Life Sci PLC - Price Monitoring Extension 6 days, 6 hours ago Tiziana Life Sci PLC - Result of GM 1 week ago Tiziana Life Sci PLC - Holding(s) in Company 1 week ago [...] Add Tiziana Life Sciences to alerts Bookmark data-twitter-title="$TILS Tiziana Life Sciences has four submissions accepted to virtual ASCO event http://tinyurl.com/yctqxo8t via @proactive_UK @tizianals #TILS " data-title="Tiziana Life Sciences has four submissions accepted to virtual ASCO event" data-description="The American Society of Clinical Oncology attracts the cream of the industry to its annual conference" data-url="[...]" > 2 min read Prev article Health Tiziana chief scientist discusses its 'pioneering' inhalation technology and novel COVID-19 approach 2 min read Next article Only registered members can use this feature. Register or Login About Meet the team Contact T&C Work for us Advertising Follow us on: © Proactive Investors 2019. Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us [...]. Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. [...]. var adverts = {"PageAdvert":[],"AdvertPosition":[{"Advert":{"id":"21","advert_position_id":"5","advert_type_id":"2","title":"Content page - Sidebar - UK - News","url":"","file":"","header_code":"googletag.cmd.push(function() { var mapping = googletag.sizeMapping(). addSize([1200, 0], [300, 250]). addSize([992, 0], [230,190]). addSize([768, 0], [170,140]). addSize([576, 0], [[510, 170], [468, 60], [300, 250], [300, 50], [320, 50], [320, 100]]). addSize([468, 0], [[468, 60], [300, 250], [300, 50], [320, 50], [320, 100]]). addSize([320, 0], [[300, 250], [300, 50], [320, 50], [320, 100]]). addSize([0, 0], []). build(); googletag.defineSlot('/6519473/LUX-Content_Sidebar', [[510, 170], [300, 250], [468, 60], [300, 50], [320, 100], [170, 140], [320, 50], [230, 190]], 'div-gpt-ad-1570110319358-0').defineSizeMapping(mapping).addService(googletag.pubads()); googletag.pubads().enableSingleRequest(); googletag.pubads().collapseEmptyDivs(); googletag.pubads().setTargeting('Domains', ['UK']).setTargeting('Content_type', ['News']); googletag.enableServices(); }); googletag.cmd.push(function() { googletag.display('div-gpt-ad-1570110319358-0'); }); ","code":" ","notes":"","is_active":true,"served_counter":"0","sector_id":null,"category_id":null,"created":"2019-09-27 14:09:41","modified":"2019-10-09 09:20:08","File":[]}}]}; increaseAdvertViews(adverts); (function (i, s, o, g, r, a, m) { i['GoogleAnalyticsObject'] = r; i[r] = i[r] || function () { (i[r].q = i[r].q || []).push(arguments) }, i[r].l = 1 * new Date(); a = s.createElement(o), m = s.getElementsByTagName(o)[0]; a.async = 1; a.src = g; m.parentNode.insertBefore(a, m) })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga'); ga('create', 'UA-1840202-12', 'auto'); ga('set', 'dimension1', '|story_id:919218|news/details|LON:TILS|8420|'); ga('send', 'pageview'); let morningStarExchangeId = 151; let epic = 'TILS'; displayCompanyChart(morningStarExchangeId, epic, 300);
Read Full Thread
Follow
Reply
10/5/2020
11:19		ambyth: All > PWhite73 is a paid serial deramper. That is his job - to create and spread fear, uncertainty and doubt. His aim is to reduce positivity so that the share price does not grow which allows others / his associates to buy in cheaply and also more fluctuations in the share price which again others / his associates exploit in short trading / spread betting as well as buying in cheaply at the too low lows. He did so on the NCYT board too, and told everyone to sell out at very low share price numbers and has no credibility. Engage with him as little as possible. He wants you to engage - starve him of all responses and he will go elsewhere (eventually). He gets paid to do this. Ignore and avoid.
Read Full Thread
Follow
Reply
02/5/2020
10:47		pwhite73: The Executive Chairman Gabriele Cerrone owns 42% of the company and at today's market cap that's worth £32 million. Therefore you can be rest assured nothing whatsoever will be done to damage his investment. However there are two main problems with TILS for UK ordinary shareholders Firstly the company intends to de-list from the AIM as announced on 13/01/2020 and move from the UK to Bermuda. The Coronavirus pandemic put a temporary halt to this plan as announced on 24/04/2020. So unless they announce otherwise it is still their intention to cancel the AIM listing when restrictions on lockdown are lifted. The Coronavirus pandemic has caused far greater interest in the pharmaceutical and biotechnology sector than ever before and none more so than in the United States. Gabriel Cerrone has about four other companies in the biotech centre registered in the US so there has been no better time for synergies between his various US companies and UK based TILS. This is why he wants to cancel the AIM listing among other plans for TILS in the US. The Products Secondly TILS have two main products in clinical trial phase in the US. Foralumab at Phase I and Milciclib at Phase II. Those of you who know anything about biotech shares other than they can go up or down would be fully aware that both drugs are about 6 - 7 years and £2 billion yes not million, billion pounds away from FDA approval to license the drugs. This link might help: https://en.wikipedia.org/wiki/Cost_of_drug_development The Share Price The very existence of TILS is ultimately dependent on a US pharmaceutical major partnering with them. The alternative would be to have existing investors diluted out of existence something the Executive Chairman will never permit. The share structure is such that any vote to delist will go through as all the stock is held in nominee accounts. The two biggest nominee accounts also hold 42% of the shares. They are Bank of New York(Nominees) and Guaranty Nominees which is owned By JP Morgan of the US. A proposal to delist would never have been sounded out without first seeking their consent. As you know TILS is already listed on the NASDAQ. So unless there is a reversal in the decision to delist from the AIM the share price will continue to slide.
Read Full Thread
Follow
Reply
Tiziana Life Sciences share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
TILS
Tiziana Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200814 23:53:10